G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 May 2017: Trial registered, NCT03164057
  2. 15 Jun 2017: Trial started, NCT03164057

The trials

NCT03164057: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

State
Under way
Phase
Phase 2
People
206 taking part
Started
15 Jun 2017
Primary completion
20 Sep 2025
Arms
AZA+ADE | AZA+FLAG+Ida | AE | MA | Asp+AraC
Results
None posted
  1. 23 May 2017: Trial registered
  2. 15 Jun 2017: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.